BN Business News
Add your company to Business Communicator →

Konkurencja i konsument · 02/08/1995

Glaxo plc Agrees to Divest Assets and Obtain Commission Approval for Migraine Drug Acquisitions

Glaxo plc has agreed to settle allegations of prohibited trade practices by divesting Wellcome's non-injectable drug research and development assets within nine months, and obtaining Commission approval for future acquisitions of migraine drug entities for ten years.

Source: Federal Register — Federal Trade CommissionOpen original release →